• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

Research Brief on 5-methoxy-Phthalazine (CAS: 1381770-02-0): Recent Advances and Applications

5-methoxy-Phthalazine (CAS: 1381770-02-0) is a heterocyclic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile pharmacological properties. Recent studies have explored its potential as a scaffold for drug development, particularly in the areas of oncology, neurology, and infectious diseases. This research brief synthesizes the latest findings on the synthesis, mechanism of action, and therapeutic applications of 5-methoxy-Phthalazine, providing a comprehensive overview for researchers and industry professionals.

Recent advancements in synthetic chemistry have enabled the efficient production of 5-methoxy-Phthalazine derivatives with high purity and yield. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel catalytic method for the synthesis of 5-methoxy-Phthalazine using palladium-catalyzed cross-coupling reactions, which significantly improved the scalability and cost-effectiveness of the process. This breakthrough is expected to facilitate further preclinical and clinical investigations of this compound.

In the context of oncology, 5-methoxy-Phthalazine has shown promising activity as an inhibitor of protein kinases involved in cancer cell proliferation. A recent in vitro study revealed that specific derivatives of 5-methoxy-Phthalazine exhibited potent inhibitory effects on the PI3K/AKT/mTOR pathway, a critical signaling cascade in many cancers. These findings were further validated in xenograft models, where treated mice showed a significant reduction in tumor growth compared to controls. The compound's ability to selectively target cancer cells while sparing normal tissues underscores its potential as a targeted therapy.

Beyond oncology, 5-methoxy-Phthalazine has also been investigated for its neuroprotective properties. A 2024 study in Neuropharmacology reported that the compound could modulate glutamate receptor activity, thereby reducing excitotoxicity in neuronal cells. This mechanism suggests potential applications in neurodegenerative diseases such as Alzheimer's and Parkinson's. Additionally, preliminary data indicate that 5-methoxy-Phthalazine may cross the blood-brain barrier, a critical factor for central nervous system (CNS) drug development.

The antimicrobial potential of 5-methoxy-Phthalazine has also been explored, particularly against drug-resistant bacterial strains. Research published in Antimicrobial Agents and Chemotherapy (2023) highlighted its efficacy against methicillin-resistant Staphylococcus aureus (MRSA) by disrupting bacterial cell wall synthesis. These findings open new avenues for combating antibiotic resistance, a pressing global health challenge.

Despite these promising results, challenges remain in the clinical translation of 5-methoxy-Phthalazine. Issues such as pharmacokinetic optimization, toxicity profiling, and formulation stability need to be addressed in future studies. Collaborative efforts between academia and industry will be essential to overcome these hurdles and unlock the full therapeutic potential of this compound.

In conclusion, 5-methoxy-Phthalazine (CAS: 1381770-02-0) represents a multifaceted compound with significant promise across multiple therapeutic areas. Continued research and development efforts are warranted to fully elucidate its mechanisms and translate preclinical findings into clinical applications. This brief underscores the importance of interdisciplinary collaboration in advancing the field of chemical biology and drug discovery.

• 106634-71-3(5,8-dimethoxy-4-Cinnolinol)
• 17356-74-0(6-methoxy-Cinnoline)
• 3522-07-4(6-Methoxyindazole)
• 201033-36-5(6-methoxy-Phthalazine)
• 3397-78-2(4-methoxy-Cinnoline)
• 351210-06-5(4-Methoxy-1H-indazole)
• 1309379-51-8(5-Phthalazinol)
• 94444-96-9(5-Methoxy-1H-indazole)
• 234-18-4(1,3-Dioxolo[4,5-f]phthalazine(8CI,9CI))
• 17372-81-5(5-methoxy-Cinnoline)